Fierce Pharma

JANUARY 19, 2024

A jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in federal court in the Southern District of New York. | A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades.

360

360

MedCity News

JANUARY 19, 2024

The former Pfizer statistician worked on the clinical trial for the Covid-19 drug Paxlovid. A jury found the employee guilty of insider trading for transactions made before clinical data for the antiviral were publicly announced.

Biopharma 145

Biopharma Pharma 145

Fierce Pharma

JANUARY 19, 2024

Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021.

312

312

MedCity News

JANUARY 19, 2024

AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.

Healthcare 139

Healthcare Healthcare 139

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JANUARY 19, 2024

More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnose | More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients.

FDA 307

FDA Patients 307

Clarivate

JANUARY 19, 2024

Over half of research office leaders say researchers are disengaged. How can you close the gap to win more funding? In late 2023, Research Professional News, an editorially independent part of Clarivate , surveyed research office leaders and staff as well as researchers around the world, taking a close look at the challenges facing them today and in the future.

Leads 114

Leads Competition Government 114

MedCity News

JANUARY 19, 2024

Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV.

Medical 112

Medical Patients Biopharma 112

Fierce Pharma

JANUARY 19, 2024

Use of Amgen’s osteoporosis drug Prolia by those with advanced chronic kidney disease (CKD) can increase the risk of calcium loss in the blood, according to the FDA. | Use of Amgen’s osteoporosis drug Prolia by those with advanced chronic kidney disease (CKD) can increase the risk of calcium loss in the blood, according to the FDA. The U.S. regulator has added a boxed warning for the blockbuster treatment, which has been on the market for 14 years and loses patent protection next year.

FDA 208

FDA Marketing 208

European Pharmaceutical Review

JANUARY 19, 2024

According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. Currently in Phase I development , the antibiotic’s novel mechanism of action was showcased through its effectiveness against the pathogen in in vitro studies.

Manufacturing 98

Manufacturing Medicine Leads Pharmaceutical 98

Fierce Pharma

JANUARY 19, 2024

Injectable formulations are the fastest growing segment in the pharmaceutical industry. According to Precedence Research, the global injectable drug delivery market reached U.S. | Simplifying the administration of complex injectables for reconstitution, liquid/liquid mixing and the sequential delivery of multiple liquid drugs.

Medical 130

Medical Pharmaceutical Marketing 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

European Pharmaceutical Review

JANUARY 19, 2024

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations. An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable,

Pharmacology 98

Pharmacology Patients Pharmaceutical Medicine 98

pharmaphorum

JANUARY 19, 2024

AstraZeneca gets its first approval for oral Factor D inhibitor danicopan, in Japan, for treatment of paroxysmal nocturnal haemoglobinuria

114

114

MedCity News

JANUARY 19, 2024

The psychiatric collaborative care model offers an opportunity to mitigate burnout by reducing the burden placed on primary care providers (PCPs) and more effectively supporting their patients with behavioral health needs.

Patients 106

Patients Physicians 106

Referral MD

JANUARY 19, 2024

How do healthcare providers benefit from patient engagement tools and other healthcare software solutions? Patient-centric care is more critical than ever in today’s fast-paced healthcare landscape. Healthcare providers must deliver high-quality medical services and engage with patients effectively and efficiently. Patient engagement, referral management, and Customer Relationship Management (CRM) software have become powerful tools to achieve these goals.

Management 94

Management Patients CRM Customer Relationship Management 94

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

MedCity News

JANUARY 19, 2024

Hospitals weathered one of their most challenging years in 2022, with median operating margins staying in the red throughout most of the year. Those money problems proved to be a major factor shaping last year’s M&A transactions — financial pressures influenced 28% of hospital M&A deals last year, up from 15% in 2022, a new report showed.

99

99

pharmaphorum

JANUARY 19, 2024

Manufacturing problems have scuppered Satsuma Pharmaceuticals’ chances of a timely FDA approval for its intranasal migraine therapy STS101. The drug – a new dry powder intranasal formulation of the well-established migraine therapy dihydroergotamine mesylate (DHE) – was submitted for approval in the US last March as an easy-to-use, portable treatment option for acute migraine attacks, with or without aura, in adult patients.

FDA 94

FDA Manufacturing Pharmaceutical Patients 94

MedCity News

JANUARY 19, 2024

By adopting integrated care models, providers and payors can ensure a seamless continuum of care for older adults.

Physicians 116

Physicians 116

Pharmaceutical Commerce

JANUARY 19, 2024

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

Healthcare 100

Healthcare Healthcare 100

Advertisement

pharmaphorum

JANUARY 19, 2024

CG Oncology joins the queue of US biotech companies hoping to complete an IPO, aiming to raise $181m for its late-stage bladder cancer therapy.

100

100

Pharmaceutical Technology

JANUARY 19, 2024

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.

Pharma 98

Pharma 98

Pharmaceutical Commerce

JANUARY 19, 2024

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.

Medicine 80

Medicine Patients Healthcare Healthcare 80

Clarivate

JANUARY 19, 2024

Planning for the year ahead in the intellectual property (IP) space is increasingly challenging. While the unknowns of AI are top of mind, there are many variables in the IP legal industry projected to influence 2024. Practitioners can expect to see more integrations and toolsets that combine previously separate workflows; China will continue to influence the IP and innovation landscape; litigation is predicted to rise with the increase of infringing products; and new jurisdictions, such as the

Management 59

Management Consulting Professional Services Sales 59

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

PharmaTimes

JANUARY 19, 2024

New stroke therapy delivers electrical pulses to the brain

96

96

Pharmaceutical Technology

JANUARY 19, 2024

The layoffs will free cash resources that will extend financial runways and focus pipeline developmental efforts.

Pharma 69

Pharma 69

PharmaTimes

JANUARY 19, 2024

Company will present vital findings at SRI annual meeting

94

94

Referral MD

JANUARY 19, 2024

Accurate information for personalized, value based care In a world where value-based care is prioritized, healthcare providers ACOs, FQHCs, Healthcare Systems, and Hospitals must comprehensively understand a patient’s health to effectively manage costs, mitigate risks, and deliver high-quality, personalized care. A key aspect of achieving these goals is ensuring that the patient’s health conditions are accurately and wholly coded, as this plays a crucial role in determining appropria

Healthcare Provider 52

Healthcare Provider Healthcare Healthcare Management 52

Advertisement

Distribution

Pharmaceutical Commerce

JANUARY 19, 2024

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

FDA 52

FDA Patients 52

PharmExec

JANUARY 19, 2024

Today's FDA approval amends a previously granted accelerated approval for Balversa (erdafitinib) to treat patients with metastatic urothelial carcinoma whose tumors harbor FGFR3 or FGFR2 alterations following prior platinum-based chemotherapy.

FDA 52

FDA Patients 52

ALULA

JANUARY 19, 2024

There’s a reason why behavior change is so difficult : life. At some point during the quarter, week, or day when you’re diligently making progress on a behavior change, you’re going to hit a wall. L ife is going to get difficult. It’s going to derail your best laid plans and mak e it possibl e – even easy – to let go of the behavior change you were so eager to embrace for the long haul.

52

52

Clarify Health

JANUARY 19, 2024

Generative AI: The New Frontier in Healthcare Technology Healthcare Unbound episode recap: We know that AI is a transformative technology already reshaping almost every kind of business, and healthcare is no exception. But what does the future of AI in healthcare look like? On this episode of Healthcare Unbound , Clarify Health President and Co-founder Todd Gottula discusses how artificial intelligence (AI) can help healthcare professionals deliver more efficient and effective care by helping en

Healthcare 52

Healthcare Healthcare Physicians Patients 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales